Riverbridge Partners LLC Sells 51,438 Shares of OrthoPediatrics Corp. $KIDS

Key Points

• Riverbridge Partners LLC reduced its stake in OrthoPediatrics Corp. by 13.8%, selling 51,438 shares to hold 321,040 shares valued at approximately $6.9 million.
• Institutional investors own 69.05% of OrthoPediatrics, with notable activity including GAMMA Investing LLC increasing its position by 4,618.2% during the first quarter.
• OrthoPediatrics reported a negative earnings per share of ($0.11) for the last quarter, exceeding analysts' estimates, while analysts currently have a consensus rating of "Moderate Buy" with an average price target of $34.14.

Riverbridge Partners LLC cut its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 13.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 321,040 shares of the company's stock after selling 51,438 shares during the period. Riverbridge Partners LLC owned about 1.32% of OrthoPediatrics worth $6,896,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its position in OrthoPediatrics by 4,618.2% during the 1st quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock valued at $261,000 after purchasing an additional 10,391 shares in the last quarter. Goldman Sachs Group Inc. raised its position in OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock valued at $4,937,000 after purchasing an additional 106,041 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in OrthoPediatrics by 116.5% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company's stock valued at $7,173,000 after purchasing an additional 179,733 shares in the last quarter. Invesco Ltd. raised its position in OrthoPediatrics by 12.1% during the 1st quarter. Invesco Ltd. now owns 18,349 shares of the company's stock valued at $452,000 after purchasing an additional 1,986 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in OrthoPediatrics by 175.0% during the 1st quarter. SG Americas Securities LLC now owns 20,039 shares of the company's stock valued at $494,000 after purchasing an additional 12,753 shares in the last quarter. 69.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other OrthoPediatrics news, CFO Fred Hite bought 5,076 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were purchased at an average cost of $19.41 per share, for a total transaction of $98,525.16. Following the purchase, the chief financial officer directly owned 213,065 shares in the company, valued at $4,135,591.65. This represents a 2.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Trading Down 0.3%

Shares of NASDAQ:KIDS opened at $18.89 on Thursday. OrthoPediatrics Corp. has a 12-month low of $16.59 and a 12-month high of $32.00. The business's fifty day simple moving average is $20.47 and its 200-day simple moving average is $21.63. The company has a market capitalization of $473.65 million, a PE ratio of -10.55 and a beta of 1.06. The company has a current ratio of 6.66, a quick ratio of 3.43 and a debt-to-equity ratio of 0.27.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The firm had revenue of $61.08 million for the quarter, compared to the consensus estimate of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. JMP Securities set a $35.00 target price on OrthoPediatrics and gave the company a "market outperform" rating in a research report on Friday, August 8th. BTIG Research decreased their target price on OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Citigroup reiterated a "market outperform" rating on shares of OrthoPediatrics in a report on Friday, August 8th. Finally, Wall Street Zen upgraded OrthoPediatrics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $34.14.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.